Pembrolizumab Clinical Trials

425 actively recruiting trials across 86 locations

▼ -6 trials since May 2026

Also known as: 1374853-91-4, BCD-201, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide with Humanized, BCD-201, C6504H10004N1716O2036S46, Cyclophosphamide, External Beam Radiation Therapy +52 more

Pipeline

Early 1: 4Phase 1: 83Phase 2: 169Phase 3: 77Phase 4: 3Phase 1/2: 71Phase 2/3: 10

Top Sponsors

Merck Sharp & Dohme LLC31
National Cancer Institute (NCI)19
M.D. Anderson Cancer Center12
Memorial Sloan Kettering Cancer Center11
AstraZeneca9

Indications

Cancer424
Lung Cancer113
Breast Cancer59
Non Small Cell Lung Cancer44
Triple Negative Breast Cancer22

Other103 trials

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

Phase 1/2

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

Phase 1/2

A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia

Phase 2

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Phase 1

A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)

Phase 1/2

A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.

Phase 2

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

Phase 1/2

A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)

Phase 2

A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

Phase 2

A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

Phase 2

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

Phase 2

A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

Phase 2

A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

Phase 3

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 3

A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)

Phase 2

A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

Phase 1/2

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 3

A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy

Phase 2

A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

Phase 3

A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

Phase 1

ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab

Phase 1

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

N/A

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

Phase 2

Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer

Phase 1/2

CARE1 Pragmatic Clinical Trial

Phase 3

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer

Phase 2

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

Phase 2

Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma

Phase 3

Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

Phase 3

Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes

Phase 2

ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers

Phase 1

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

Phase 3

Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

Phase 2

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Phase 3

Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC

N/A

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Phase 4

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Phase 1

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Phase 1/2

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

Phase 1/2

First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

Phase 2

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Phase 2

Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia

N/A

Ixovex-1 Single Agent and Combination Therapy

Phase 1/2

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Phase 1/2

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

Phase 2

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

Phase 1/2

NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer

Phase 2

Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer

Phase 2

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

Phase 3

NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma

Phase 2

Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

Phase 2

Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma

Phase 2

Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma

Phase 2

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

Phase 2

Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)

Phase 1/2

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Phase 2

PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

Phase 2

Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

Phase 2

Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

Phase 2

Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

Phase 2

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)

Phase 2

Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01

Phase 2

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

Phase 3

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Phase 2

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Phase 2

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Phase 2

Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer

Phase 2

Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer

Phase 2

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

Phase 3

Pembrolizumab in High-risk Thyroid Cancer

Phase 2

Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

Phase 2

Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

Phase 2

Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

Phase 3

Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies

Phase 1

Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis

Phase 2

Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Phase 2

Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform

Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients

Phase 2

Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

Phase 3

Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)

SSGJ-707 in Advanced Non-Small Cell Lung Cancer

Phase 3

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Phase 1

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

Phase 1/2

Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Phase 1

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Phase 1/2

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

Phase 2

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Phase 2

Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

Phase 2/3

Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Phase 3

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Phase 2

T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma

Phase 1/2

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

Phase 1/2

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

Phase 1/2

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

Phase 1/2

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

Phase 1/2

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Phase 3

The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab

Phase 4

The Drug Rediscovery Protocol (DRUP Trial)

Phase 2

To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Phase 1/2

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

Phase 2

Birmingham, Alabama20 trials

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0347

Phase 3

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

The Kirklin Clinic of University of Alabama Birmingham Hospital

Phase 1/2

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

UAB Medicine - UAB Hospital

Phase 3

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1/2

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

University of Alabama

Phase 1

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

University of Alabama at Birmingham

Phase 2

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Central Alabama Research

Phase 3

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

O'Neal Comprehensive Cancer Center at UAB

Phase 1

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

University of Alabama at Birmingham Cancer Center

Phase 3

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

Study of Pembrolizumab and M032 (NSC 733972)

University of Alabama at Birmingham

Phase 1/2

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Alabama Oncology

Phase 3

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

University of Alabama at Birmingham Cancer Center

Phase 2

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

University of Alabama Birmingham

Phase 2

Los Angeles, California17 trials

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

UCLA ( Site 0317)

Phase 1/2

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

California Research Institute

Phase 2/3

A Study of VET3-TGI in Patients With Solid Tumors

USC/Norris Comprehensive Cancer Center

Phase 1

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Teva Investigational Site 12017

Phase 1

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

The Angeles Clinic and Research Institute - West Los Angeles Office

Phase 1

CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

USC Norris Comprehensive Cancer Center

Phase 1

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 1/2

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Cedars-Sinai Medical Center

Phase 1/2

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

Ellison Institute of Technology (EITM)

Phase 2

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 2

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

University of California at Los Angeles / Jonsson Comprehensive Cancer Center

Phase 2

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

USC Norris Comprehensive Cancer Center

Phase 2/3

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Cedars-Sinai Medical Center

Phase 2

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

Angeles Clinic and Research Center

Phase 1/2

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

START Los Angeles

Phase 1/2

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

The Angeles Clinic and Research Institute

Phase 1/2

Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

Cedars-Sinai Medical Center

Phase 1/2

Boston, Massachusetts15 trials

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Dana-Farber Cancer Institute

Phase 1

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Massachusetts General Hospital (Data Collection Only)

Phase 2

ALPINE: Maintenance Letrozole/Abemaciclib

Beth Israel Deaconess Medical Center

Phase 2

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

Massachusetts General Hospital

Phase 1

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

Beth Israel Deaconess Medical Center

Phase 1

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Brigham and Women's Hospital

Phase 2

Palbociclib and Pembrolizumab In Central Nervous System Metastases

Massachusetts General Hospital

Phase 2

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Brigham and Women's Hospital

Phase 1

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Dana Farber Cancer Institute

Phase 1/2

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 1/2

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Brigham and Women's Hospital

Phase 2

Sacituzumab Govitecan In TNBC

Beth Israel Deaconess Medical Center

Phase 2

Sacituzumab Govitecan Plus EV in Metastatic UC

Dana Farber Cancer Institute

Phase 1/2

Surgical Pembro +/- Olaparib w TMZ for rGBM

Massachusetts General Hospital

Phase 2

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Boston Medical Center

Phase 1

Phoenix, Arizona13 trials

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Local Institution - 0005

Phase 2

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Cancer Center at Saint Joseph's

Phase 3

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

HonorHealth Research Institute

Phase 1

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Clinical Trial Site

Phase 1

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Mayo Clinic - Phoenix

Phase 1

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

St. Joseph's Hospital and Medical Center

Phase 3

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Mayo Clinic Hospital

Phase 3

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Mayo Clinic Hospital in Arizona

Phase 3

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

USOR HonorHealth

Phase 1/2

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Mayo Clinic

Phase 3

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Mayo Clinic in Arizona - Phoenix ( Site 0147)

Phase 3

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Mayo Clinic Hospital in Arizona

Phase 1

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Cancer Center at Saint Joseph's

Phase 3

Houston, Texas13 trials

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

MD Anderson Cancer Center

Phase 2

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

M D Anderson Cancer Center

Phase 2

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Harris Health System - Smith Clinic

Phase 2

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

M D Anderson Cancer Center

Phase 2

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Baylor College of Medicine

Phase 2

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

MD Anderson Cancer Center

Phase 2

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

M D Anderson Cancer Center

Early 1

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

M D Anderson Cancer Center

Phase 1

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

M D Anderson Cancer Center

Phase 1

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

MD Anderson Cancer Center

Phase 2

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

M D Anderson Cancer Center

Phase 2

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

The University of Texas M. D. Anderson Cancer Center

Phase 2

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

MD Anderson Cancer Center

Phase 1

Duarte, California12 trials

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

City of Hope National Medical Center

Phase 1/2

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

City of Hope

Phase 3

A Study of ASP3082 in Adults With Advanced Solid Tumors

City of Hope National Medical Center

Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

City of Hope Cancer Center

Phase 1

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

City of Hope National Medical Center

Phase 1

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

Research Site

Phase 1/2

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

City of Hope(City of Hope National Medical Center, City of Hope Medical Center)

Phase 3

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

City of Hope

Phase 2

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

City of Hope Comprehensive Cancer Center

Phase 1

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

City of Hope Medical Center

Phase 1

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

City of Hope Cancer Center (Data Collection Only)

Phase 2

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

City of Hope

Phase 1

Tucson, Arizona10 trials

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site

Phase 3

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927)

Phase 1/2

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Center for Neurosciences

Phase 3

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Research Site

Phase 3

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

University of Arizona - Cancer Center

Phase 1

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Arizona Cancer Center at UMC North ( Site 0018)

Phase 3

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

University of Arizona Cancer Center

Phase 1/2

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

The University of Arizona Cancer Center-North Campus

Phase 2

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)

Phase 1/2

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Arizona Oncology Associates

Phase 1

Anchorage, Alaska9 trials

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Research Site

Phase 3

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Alaska Oncology and Hematology

Phase 3

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Alaska Oncology and Hematology ( Site 0039)

Phase 3

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Alaska Oncology and Hematology

Phase 1

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Alaska Oncology and Hematology

Phase 2/3

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site

Phase 3

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Alaska Oncology and Hematology, LLC

Phase 2/3

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Alaska Oncology & Hematology, LLC

Phase 3

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Anchorage Associates in Radiation Medicine

Phase 3

Tampa, Florida9 trials

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Moffitt Cancer Center ( Site 0261)

Phase 1

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Moffitt Cancer Center ( Site 0021)

Phase 2

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Moffit Cancer Center

Phase 2

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Moffitt Cancer Center

Phase 2

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

Moffitt Cancer Center

Phase 1

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Moffitt Cancer Center

Phase 2

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Moffitt Cancer Center

Phase 2

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Moffitt Cancer Center

Phase 2

Chicago, Illinois9 trials

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Ryan Nguyen

Phase 2

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

University of Chicago Comprehensive Cancer Center

Phase 2

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

Northwestern University Feinberg School of Medicine

Phase 2

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

University of Chicago Medicine Comprehensive Cancer Center

Phase 1

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

University of Chicago Medicine Comprehensive Cancer Center

Phase 2

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Northwestern University

Phase 2

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

University of Illinois

Phase 1

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

The University of Chicago Medical Center

Phase 2/3

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Northwestern Memorial Hospital ( Site 0002)

Phase 1

Atlanta, Georgia8 trials

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Emory University Hospital Midtown

Phase 2

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Emory University Hospital Midtown

Phase 2

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Grady Health System

Phase 2

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Emory University Hospital/Winship Cancer Institute

Phase 2

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Emory University Hospital Midtown

Phase 2

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Emory University/Winship Cancer Institute

Early 1

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Grady Health System

Phase 1

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Emory University Hospital Midtown

Phase 1

Scottsdale, Arizona7 trials

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Honor Health Research Institute

Phase 1

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

HonorHealth

Phase 1

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Mayo Clinic in Arizona

Phase 1/2

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Honor Health Research Institute

Phase 1

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

HonorHealth Research Institute

Phase 1/2

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Honor Health Research Institute

Phase 1

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Mayo Clinic in Arizona

Phase 1/2

New York, New York7 trials

Amping up With PemJAK

Columbia University Irving Medical Center

Phase 2

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Icahn School of Medicine at Mount Sinai

Phase 2

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Icahn School of Medicine at Mount Sinai

Phase 2

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Mount Sinai Health System

Early 1

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Weill Cornell Medicine

Phase 1/2

Pembrolizumab for Advanced NSCLC and PS 2-3

Mount Sinai Hospital

Phase 2

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Memorial Sloan Kettering Cancer Center

Phase 2

Mobile, Alabama6 trials

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Research Site

Phase 3

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Site 164

Phase 3

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

USA Mitchell Cancer Institute ( Site 0090)

Phase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

University of South Alabama, Mitchell Cancer Institute ( Site 6033)

Phase 3

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Local Institution - 0487

Phase 3

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Infirmary Cancer Care ( Site 0001)

Phase 3

San Francisco, California6 trials

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Stanford University

Phase 1

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

University of California San Francisco

Phase 2

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

University of California, San Francisco

Phase 1/2

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

UCSF Medical Center at Mission Bay ( Site 5044)

Phase 1/2

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

University of California, San Francisco

Phase 2

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

University of California, San Francisco

Phase 2

Santa Monica, California6 trials

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

UCLA

Phase 1

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Sarcoma Oncology Center

Phase 2/3

Pembrolizumab and Pemetrexed for Progressive Chordoma

Providence Saint John's Health Center

Phase 2

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Research Site

Phase 2

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

UCLA Hematology/Oncology - Parkside ( Site 0021)

Phase 2

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

UCLA Hematology/Oncology

Phase 1/2

Bethesda, Maryland6 trials

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

National Institutes of Health Clinical Center

Phase 2

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

National Institutes of Health Clinical Center

Phase 2

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

National Institutes of Health Clinical Center

Phase 2

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

National Institutes of Health Clinical Center

Phase 1/2

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

National Institutes of Health Clinical Center

Phase 2

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

National Institutes of Health Clinical Center

Phase 1

Basking Ridge, New Jersey6 trials

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

Memorial Sloan Kettering Basking Ridge (Limited protocol activities)

Phase 2

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities)

Phase 1

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)

Phase 2

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Phase 2

Philadelphia, Pennsylvania6 trials

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

Fox Chase Cancer Center

Phase 1

Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

Penn Medicine

Phase 2

Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

Fox Chase Cancer Center - Philadelphia

Phase 2

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Phase 1

Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma

Abramson Cancer Center at the University of Pennsylvania

Phase 2

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Abramson Cancer Center of the University of Pennsylvania

Phase 1

Gilbert, Arizona5 trials

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Banner MD Anderson Cancer Center ( Site 0066)

Phase 3

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Banner Gateway Medical Center

Phase 2

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Banner MD Anderson Cancer Center ( Site 0181)

Phase 3

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Banner MD Anderson Cancer Center ( Site 0001)

Phase 1/2

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Banner MD Anderson Cancer Center

Phase 1/2

La Jolla, California5 trials

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

University of California at San Diego Moores Cancer Center

Phase 1/2

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

University of California San Diego (Ucsd)-Moores Cancer Center

Phase 1/2

Pembrolizumab in Treating Participants With Leukoplakia

UC San Diego Moores Cancer Center

Phase 2

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Moores Cancer Center UC San Diego Health

Phase 1

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Moores Cancer Center /ID# 267782

Phase 2/3

New Haven, Connecticut5 trials

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Yale University

Phase 1

CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

Yale University

Phase 2

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

Yale University School of Medicine

Phase 1

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Yale Smilow Cancer Hospital

Phase 2

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Yale Cancer Center

Phase 3

Miami, Florida5 trials

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

University of Miami

Phase 2

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Baptist Alliance MCI

Phase 2

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

University of Miami

Phase 2

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

University of Miami

Phase 1

ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

University of Miami

Phase 2

Rochester, Minnesota5 trials

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Mayo Clinic

Phase 2

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic in Rochester

Phase 4

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Mayo Clinic in Rochester

Phase 2

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Mayo Clinic in Rochester

Phase 2

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

Mayo Clinic in Rochester

Phase 2

Huntsville, Alabama4 trials

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Clearview Cancer Institute

Phase 3

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Clearview Cancer Institute

Phase 3

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Clearview Cancer Institute

Phase 3

Little Rock, Arkansas4 trials

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060)

Phase 3

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Arkansas Urology Associates

Phase 2

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

CARTI Cancer Center ( Site 0006)

Phase 3

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

University of Arkansas for Medical Sciences

Phase 3

Orange, California4 trials

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

University of California Irvine Medical Center

Phase 1

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

D3 Bio Investigative Site 0402

Phase 1/2

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045)

Phase 1/2

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

Chao Family Comprehensive Cancer Center University of California, Irvine

Phase 2

Sacramento, California4 trials

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

University of California Davis Comprehensive Cancer Center

Phase 1/2

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

University of California Davis Comprehensive Cancer Center

Phase 1

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

University of California Davis Comprehensive Cancer Center

Phase 1

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

UC Davis

Early 1

Baltimore, Maryland4 trials

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Johns Hopkins Hospital

Phase 1/2

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Sidney Kimmel Comprehensive Cancer Center

Phase 2

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

SKCCC Johns Hopkins

Phase 2

Buffalo, New York4 trials

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Roswell Park Cancer Institute

Phase 2

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 2

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Roswell Park Cancer Institute

Phase 2

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Roswell Park Cancer Institute

Phase 2

Pittsburgh, Pennsylvania4 trials

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

UPMC Hillman Cancer Center

Phase 2

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

UPMC Hillman Cancer Center

Phase 2

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

UPMC Hillman Cancer Center

Phase 2

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

UPMC Hillman Cancer Center ( Site 1904)

Phase 1/2

Chandler, Arizona3 trials

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Ironwood Cancer and Research Center

Phase 3

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Ironwood Cancer & Research Centers ( Site 0066)

Phase 3

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Ironwood Cancer and Research Center

Phase 3

Aurora, Colorado3 trials

A Study of EBC-129 in Advanced Solid Tumours

University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center

Phase 1

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Call for Information (Investigational Site 0019)

Phase 1/2

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

University of Colorado Cancer Center

Phase 2

Washington D.C., District of Columbia3 trials

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Sibley Memorial Hospital

Phase 2

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

MedStar Georgetown University Hospital

Phase 2

Renal Retention in High Grade Upper Tract Urothelial Cancer

Johns Hopkins University: Sibley Memorial Hospital

Phase 2

Jacksonville, Florida3 trials

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Mayo Clinic Jacksonville

Phase 1

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Mayo Clinic in Florida

Phase 1/2

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Mayo Clinic

Phase 1

Indianapolis, Indiana3 trials

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center

Phase 2

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Indiana University Simon Cancer Center

Phase 1/2

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Phase 2

Iowa City, Iowa3 trials

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

University of Iowa Health Care

Phase 1

Palbociclib and Pembrolizumab in Sarcoma

University of Iowa Hospitals & Clinics

Phase 1

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

University of Iowa Hospitals and Clinics

Phase 2

Ann Arbor, Michigan3 trials

Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

Veterans Affairs Ann Arbor Healthcare System

Phase 1

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

University of Michigan Comprehensive Cancer Center

Phase 2

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer

University of Michigan Comprehensive Cancer Center

Phase 2

Portland, Oregon3 trials

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

Providence Portland Cancer Institute - Franz Clinic

Phase 1

Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery

University of Wisconsin - Madison

N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.